Guotai Haitong Securities: Innovation drug investment and financing are warming up, and the clinical CRO industry is expected to continue to improve in prosperity
Source: Finance China Society On February 6, Guotai Haitong Securities published a research report analyzing that, against the backdrop of a rebound in innovative drug investment, financing, and R&D activities, a regulatory focus on efficiency, and the upgrade of clinical execution models towards data-driven and intelligent systems, the demand for clinical CROs has a foundation for recovery, and industry prosperity is expected to gradually improve. Innovation… Web link
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Guotai Haitong Securities: Innovation drug investment and financing are warming up, and the clinical CRO industry is expected to continue to improve in prosperity
Source: Finance China Society On February 6, Guotai Haitong Securities published a research report analyzing that, against the backdrop of a rebound in innovative drug investment, financing, and R&D activities, a regulatory focus on efficiency, and the upgrade of clinical execution models towards data-driven and intelligent systems, the demand for clinical CROs has a foundation for recovery, and industry prosperity is expected to gradually improve. Innovation… Web link